COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Archive ouverte

Kroemer, Marie | Spehner, Laurie | Vettoretti, Lucie | Bouard, Adeline | Eberst, Guillaume | Pili Floury, Sebastien | Capellier, Gilles | Lepiller, Quentin | Orillard, Emeline | Mansi, Laura | Clairet, Anne-Laure | Westeel, Virginie | Limat, Samuel | Dubois, Maxime | Malinowski, Léa | Bohard, Louis | Borg, Christophe | Chirouze, Catherine | Bouiller, Kevin

Edité par CCSD ; Elsevier -

International audience. Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04365322) that included 60 COVID-19 convalescent patients (1-month post infection) in two cohorts respectively entitled mild illness and severe pneumonia. The monitoring of peripheral immune responses was performed using IFNᵧ ELISpot assay. The serology index of each patient was investigated at the same time. Patients with severe pneumonia were older and had more comorbidities than patients with mild illness. T-cell responses in term of frequency and intensity were clearly distinct between mild illness and severe pneumonia patients. Furthermore, our results demonstrated that recent history of COVID-19 did not hamper viral memory T-cell pool against common viruses (Cytomegalovirus, Epstein-Barr-virus and Flu-virus). The presence of potent adaptive immunity even in patients who underwent severe pneumonia sustain the rationale for the development of protective therapeutics against SARS-CoV-2.

Suggestions

Du même auteur

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Archive ouverte | Mansi, Laura | CCSD

International audience. Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive e...

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. Quelle formation académique pour les nouvelles missions de pharmacie clinique à l’officine ? Exemple du bilan partagé de médication du sujet âgé

Archive ouverte | Adotévi, Olivier | CCSD

International audience. PURPOSE Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase...

Persistent COVID-19 in an immunocompromised host treated by SARS-CoV-2-specific monoclonal antibodies

Archive ouverte | Bailly, Benoit | CCSD

International audience

Chargement des enrichissements...